OKLAHOMA CITY--(BUSINESS WIRE)--The law firm of Federman & Sherwood has initiated an investigation into Advaxis, Inc. (NASDAQ: ADXS) with respect to possible violations of federal securities laws.
Advaxis, Inc. (“Advaxis”) is a clinical stage biotechnology company focused on the development of cancer therapies. Federman & Sherwood is investigating whether Advaxis and certain of its officers and/or directors have violated the Securities Exchange Act of 1934.
SeekingAlpha published on January 21, 2015 an article which alleges that in a recent corporate presentation Advaxis misrepresented the tumor response data for its ADXS-HPV compound, overstating its effectiveness in shrinking tumors. The article further alleges that Advaxis misled investors regarding the design of the planned Phase 3 trial. On this news, the shares of Advaxis fell $3.39 per share to close at $8.37 per share.
If you currently own common stock in Advaxis, Inc., have any information to assist in our investigation, have questions or concerns regarding this notice or your rights or interests in this matter, please contact Federman & Sherwood. Federman & Sherwood has extensive nationwide experience in representing investors in securities, derivative and merger-related shareholder class actions, and has been appointed as lead counsel in multiple complex cases across the country.